Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I/II study of Allocetra in primary Knee OsteoArthritis patients

Next Previous
Trial Profile

Phase I/II study of Allocetra in primary Knee OsteoArthritis patients

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 21 Apr 2026 According to an Enlivex media release, company announced that it has received Clinical Trial Application (CTA) approval by the Danish Medicines Agency (DKMA) for this trial.
  • 23 Mar 2026 According to Enlivex media release, company is looking forward to enroll the first patients in this trial.
  • 23 Mar 2026 According to an Enlivex media release, company announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for Allocetra for the treatment of patients with moderate-to-severe age-related symptomatic primary knee osteoarthritis (OA).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top